11:49 AM EST - Resverlogix Corp. : announced that it has completed dosing in ASSURE, a Phase 2b clinical trial evaluating RVX-208, Resverlogix's first-in-class orally active BET-protein inhibitor, using intra-vascular ultrasound (IVUS) in high-risk cardiovascular patients with low HDL and ApoA-I. Resverlogix Corp.
shares T.RVX are trading up $0.06 at $2.73.
